Literature DB >> 28724765

The Translesion Polymerase Pol η Is Required for Efficient Epstein-Barr Virus Infectivity and Is Regulated by the Viral Deubiquitinating Enzyme BPLF1.

Ossie F Dyson1, Joseph S Pagano2,1,3, Christopher B Whitehurst4.   

Abstract

Epstein-Barr virus (EBV) infection and lytic replication are known to induce a cellular DNA damage response. We previously showed that the virally encoded BPLF1 protein interacts with and regulates several members of the translesion synthesis (TLS) pathway, a DNA damage tolerance pathway, and that these cellular factors enhance viral infectivity. BPLF1 is a late lytic cycle gene, but the protein is also packaged in the viral tegument, indicating that BPLF1 may function both early and late during infection. The BPLF1 protein expresses deubiquitinating activity that is strictly conserved across the Herpesviridae; mutation of the active site cysteine results in a loss of enzymatic activity. Infection with an EBV BPLF1 knockout virus results in decreased EBV infectivity. Polymerase eta (Pol η), a specialized DNA repair polymerase, functions in TLS and allows for DNA replication complexes to bypass lesions in DNA. Here we report that BPLF1 interacts with Pol η and that Pol η protein levels are increased in the presence of functional BPLF1. BPLF1 promotes a nuclear relocalization of Pol η molecules which are focus-like in appearance, consistent with the localization observed when Pol η is recruited to sites of DNA damage. Knockdown of Pol η resulted in decreased production of infectious virus, and further, Pol η was found to bind to EBV DNA, suggesting that it may allow for bypass of damaged viral DNA during its replication. The results suggest a mechanism by which EBV recruits cellular repair factors, such as Pol η, to sites of viral DNA damage via BPLF1, thereby allowing for efficient viral DNA replication.IMPORTANCE Epstein-Barr virus is the causative agent of infectious mononucleosis and infects approximately 90% of the world's population. It causes lymphomas in individuals with acquired and innate immune disorders and is strongly associated with Hodgkin's lymphoma, Burkitt's lymphoma, diffuse large B-cell lymphomas, nasopharyngeal carcinoma (NPC), and lymphomas that develop in organ transplant recipients. Cellular DNA damage is a major determinant in the establishment of oncogenic processes and is well studied, but there are few studies of endogenous repair of viral DNA. This work evaluates how EBV's BPLF1 protein and its conserved deubiquitinating activity regulate the cellular DNA repair enzyme polymerase eta and recruit it to potential sites of viral damage and replication, resulting in enhanced production of infectious virus. These findings help to establish how EBV enlists and manipulates cellular DNA repair factors during the viral lytic cycle, contributing to efficient infectious virion production.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  BPLF1; DNA repair; Epstein-Barr virus; Pol η; deubiquitination; herpesviruses; infectivity; translesion synthesis

Mesh:

Substances:

Year:  2017        PMID: 28724765      PMCID: PMC5599766          DOI: 10.1128/JVI.00600-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  Interaction of human DNA polymerase eta with monoubiquitinated PCNA: a possible mechanism for the polymerase switch in response to DNA damage.

Authors:  Patricia L Kannouche; Jonathan Wing; Alan R Lehmann
Journal:  Mol Cell       Date:  2004-05-21       Impact factor: 17.970

2.  Epstein-Barr virus BPLF1 deubiquitinates PCNA and attenuates polymerase η recruitment to DNA damage sites.

Authors:  Christopher B Whitehurst; Cyrus Vaziri; Julia Shackelford; Joseph S Pagano
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

3.  Regulation of translesion synthesis DNA polymerase eta by monoubiquitination.

Authors:  Marzena Bienko; Catherine M Green; Simone Sabbioneda; Nicola Crosetto; Ivan Matic; Richard G Hibbert; Tihana Begovic; Atsuko Niimi; Matthias Mann; Alan R Lehmann; Ivan Dikic
Journal:  Mol Cell       Date:  2010-02-12       Impact factor: 17.970

4.  Epstein-Barr virus deubiquitinase downregulates TRAF6-mediated NF-κB signaling during productive replication.

Authors:  Shinichi Saito; Takayuki Murata; Teru Kanda; Hiroki Isomura; Yohei Narita; Atsuko Sugimoto; Daisuke Kawashima; Tatsuya Tsurumi
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

5.  A gammaherpesvirus ubiquitin-specific protease is involved in the establishment of murine gammaherpesvirus 68 infection.

Authors:  Sara Gredmark-Russ; Marisa K Isaacson; Lisa Kattenhorn; Evelyn J Cheung; Nicki Watson; Hidde L Ploegh
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

6.  Cleavage specificity of the UL48 deubiquitinating protease activity of human cytomegalovirus and the growth of an active-site mutant virus in cultured cells.

Authors:  Eui Tae Kim; Se Eun Oh; Yun-Ok Lee; Wade Gibson; Jin-Hyun Ahn
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

7.  Human DNA polymerase eta activity and translocation is regulated by phosphorylation.

Authors:  Yih-Wen Chen; James E Cleaver; Zafer Hatahet; Richard E Honkanen; Jang-Yang Chang; Yun Yen; Kai-Ming Chou
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-22       Impact factor: 11.205

8.  Enzymatic blockade of the ubiquitin-proteasome pathway.

Authors:  Robert Ernst; Jasper H L Claessen; Britta Mueller; Sumana Sanyal; Eric Spooner; Annemarthe G van der Veen; Oktay Kirak; Christian D Schlieker; Wilhelm A Weihofen; Hidde L Ploegh
Journal:  PLoS Biol       Date:  2011-03-29       Impact factor: 8.029

9.  In vivo bypass of 8-oxodG.

Authors:  Gina P Rodriguez; Joseph B Song; Gray F Crouse
Journal:  PLoS Genet       Date:  2013-08-01       Impact factor: 5.917

10.  Epstein-Barr virus large tegument protein BPLF1 contributes to innate immune evasion through interference with toll-like receptor signaling.

Authors:  Michiel van Gent; Steven G E Braem; Annemieke de Jong; Nezira Delagic; Janneke G C Peeters; Ingrid G J Boer; Paul N Moynagh; Elisabeth Kremmer; Emmanuel J Wiertz; Huib Ovaa; Bryan D Griffin; Maaike E Ressing
Journal:  PLoS Pathog       Date:  2014-02-20       Impact factor: 6.823

View more
  7 in total

1.  Host translesion polymerases are required for viral genome integrity.

Authors:  Sebastian Zeltzer; Pierce Longmire; Marek Svoboda; Giovanni Bosco; Felicia Goodrum
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-10       Impact factor: 12.779

Review 2.  Replication Compartments-The Great Survival Strategy for Epstein-Barr Virus Lytic Replication.

Authors:  Atsuko Sugimoto
Journal:  Microorganisms       Date:  2022-04-25

3.  Small molecule screening identifies inhibitors of the Epstein-Barr virus deubiquitinating enzyme, BPLF1.

Authors:  Sage L Atkins; Safiyyah Motaib; Laura C Wiser; Sharon E Hopcraft; Paul B Hardy; Julia Shackelford; Peter Foote; Ashley H Wade; Blossom Damania; Joseph S Pagano; Kenneth H Pearce; Christopher B Whitehurst
Journal:  Antiviral Res       Date:  2019-11-08       Impact factor: 5.970

Review 4.  Epstein-Barr Virus Hijacks DNA Damage Response Transducers to Orchestrate Its Life Cycle.

Authors:  Pok Man Hau; Sai Wah Tsao
Journal:  Viruses       Date:  2017-11-16       Impact factor: 5.048

Review 5.  Gammaherpesviral Tegument Proteins, PML-Nuclear Bodies and the Ubiquitin-Proteasome System.

Authors:  Florian Full; Alexander S Hahn; Anna K Großkopf; Armin Ensser
Journal:  Viruses       Date:  2017-10-21       Impact factor: 5.048

6.  BGLF2 Increases Infectivity of Epstein-Barr Virus by Activating AP-1 upon De Novo Infection.

Authors:  Natsuno Konishi; Yohei Narita; Fumiya Hijioka; H M Abdullah Al Masud; Yoshitaka Sato; Hiroshi Kimura; Takayuki Murata
Journal:  mSphere       Date:  2018-04-25       Impact factor: 4.389

7.  Harnessing the Genetic Plasticity of Porcine Circovirus Type 2 to Target Suicidal Replication.

Authors:  Agm Rakibuzzaman; Pablo Piñeyro; Angela Pillatzki; Sheela Ramamoorthy
Journal:  Viruses       Date:  2021-08-24       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.